Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by priceless2on Oct 22, 2017 9:38am
156 Views
Post# 26841874

RE:RE:RE:RE:RE:RE:RE:Market Passion in the affirmative...NOT!

RE:RE:RE:RE:RE:RE:RE:Market Passion in the affirmative...NOT!Led,

i am of the opinion , that RVX will not have any issue with getting financing 
Over the next few months to move BOM forward. The science is way too important and i
believe, a lot of people realize this. I would love to see a major BP take a stab at us but think
DM is most likely asking way too much at this point of the trial for BP to pay. However I am sure 
a BP will pay close to the EV charts we have seen if BOM gets approved , until then lets hope that 
another large institution or a regional pharma ponies up for a regional license deal to even out the ownership, We did hear last year at the AGM that deal got away, maybe this time it will be done !!
Bullboard Posts